W
hooping cough (pertussis) is caused by the Gram-negative bacterium Bordetella pertussis. The disease is still a health problem throughout the world even though vaccination against it has been used for 50 years. Despite a long history of vaccination with high coverage in children, a resurgence of pertussis has been observed in many countries, including, Australia, Canada, France, Germany, The Netherlands, Norway, Poland, and the United States (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) .
In Europe, countries use different vaccination strategies against pertussis (11) (Table 1) . Recently, in all European countries (except Poland) whole-cell pertussis vaccines have been replaced by acellular vaccines in which only 1 to 5 protein components (in different formulations) of B. pertussis are included: pertussis toxin (PT), pertactin (PRN), filamentous hemagglutinin (FHA), fimbrial protein type 2 (FIM2), and fimbrial protein type 3 (FIM3) (12) . In many European countries, differences in these proteins have been found between B. pertussis vaccine strains and circulating isolates (13) (14) (15) (16) (17) (18) (19) . A new, possibly more virulent, B. pertussis lineage (designated the ptxP3 lineage) has been recently described (20) . The ptxP3 lineage now predominates in several European countries (18, (20) (21) (22) and is also found in Australia (23) . Moreover, the emergence of B. pertussis isolates not expressing the vaccine antigen PRN was described in France (22, 24) . Clinical isolates deficient in PRN were also reported in Italy and Japan (25, 26) . For more effective vaccination programs to prevent pertussis, it is important to monitor changes in bacterial populations and to study the impact of these changes on the incidence of disease.
Our previous EUpertstrain I and II studies have shown that the recent epidemics in Europe are associated with clonal expansion of certain B. pertussis strains (27) (28) (29) The purpose of this EUpertstrain III study was to investigate the possible effects of different vaccination strategies on the population structure of B. pertussis and to identify changes which have occurred in the bacterial population during the last 10 years in countries where acellular vaccines have been in use. In this study, we used the same method, PFGE analysis, to identify and trace profiles represented in material collected from seven countries participating in the EUpertstrain III study. For comparison, EUpertstrain I and II culture collections were also included.
(The results of this study were presented in part as a poster at the 9th International Bordetella Symposium, Baltimore, MD, 30 September to 3 October 2010.)
MATERIALS AND METHODS
Vaccination programs. The pertussis vaccination programs used in nine countries participating in the EUpertstrain I to III studies are shown in Table 1 .
Criteria for selection of clinical isolates. In order to make data comparable, the criteria for selection of isolates in the EUpertstrain III project were the same as those used in EUpertstrain I and II projects. The selection criteria included the following: B. pertussis isolates from different areas and not from local outbreaks, equal number of isolates from partially vaccinated and unvaccinated individuals, and isolates from individuals Ͻ5 years of age. The age distribution of the 140 individuals from whom B. pertussis was isolated in the period from 2007 to 2009 was as follows: 33 were Յ1 month, 20 were 1 to 2 months, 8 were 2 to 3 months, 22 were 4 to 6 months, 11 were 7 to 12 months, 22 were 1 to 5 years, 14 were 6 to 18 years, and 10 were older than 18 years. Of the 24 individuals older than 5 years, 4 were from Denmark, 3 were from Finland, 4 were from France, 7 were from Norway, and 6 were from the United Kingdom.
Collection of isolates. In the EUpertstrain I project, a total of 102 isolates were collected from children in five countries, i.e., Finland, France, Germany, The Netherlands, and Sweden, in the period from 1998 to 2001. In the EUpertstrain II project, a total of 154 isolates were collected from children in the five countries participating in the EUpertstrain I project plus Denmark, Poland, and the United Kingdom in the period from 2004 to 2005. In the EUpertstrain III project, 140 isolates were collected in seven countries, i.e., Finland, France, The Netherlands, Sweden, Denmark, United Kingdom, and Norway, in the period from 2007 to 2009. The numbers of isolates collected among the nine countries during the three study periods are shown in Table 2 .
PFGE analysis. All isolates collected during the three study periods were analyzed by pulsed-field gel electrophoresis (PFGE) at the Swedish Institute for Communicable Disease Control (SMI) according to the standardized recommendations for typing of B. pertussis (30) , with the modifications described in reference 31. The PFGE analyses of all isolates tested were performed by the same person (A.A.) at SMI. The PFGE method has been proven to be stable and has high resolution. The profiles were analyzed by using BioNumerics software version 4.61 (Applied Maths, NV, Belgium). Initially major PFGE groups were determined as described by Khattak and Matthews (32) , i.e., PFGE groups I, II, III, and IV (19, 22, 27) . Later, PFGE groups were defined as distinct DNA band patterns if they differed by at least one band and were designated BpSR1, BpSR2, BpSR3, etc., for those isolates first (13) 43 (11) 33 (8) 21 (5) 241 (61) a All isolates were typed at the Swedish Institute for Communicable Disease Control, Stockholm, Sweden.
detected in Sweden (31) . Isolates first identified in a country other than Sweden, such as Finland, were designated BpFINR1, BpFINR2, etc. A cluster analysis was performed using BioNumerics software with the unweighted-pair group method using the arithmetic average algorithm with 2% band tolerance and 1.5% optimization settings. For the purpose of comparability, the same band tolerance and optimization settings used in the previous EUpertstrain study (28) were used. Strains 18323 (PFGE cluster I), Tohama I (PFGE cluster II), Bp134 (PFGE cluster III), B902 (PFGE cluster IV␣), FR743 (PFGE cluster IV␤), FIN12 (PFGE cluster IV␥), and FR287 (PFGE cluster V) were included in the dendrogram as reference strains (19, 27) . Statistical analysis. Fisher's exact test or the chi-square test was used for statistical comparison of the frequencies of five PFGE profiles between different age groups. P values (two sided) of Ͻ0.05 were considered significant.
RESULTS
Altogether, 396 isolates collected in the three study periods produced 81 distinct PFGE profiles, and most of them are included in cluster IV (Fig. 1) . In the 102 isolates belonging to the collection from the period from 1998 to 2001, 33 profiles were identified. In Of the 81 distinct profiles, 5 (BpSR11, BpSR10, BpSR3, BpSR5, and BpSR12) were found in 21 to 91 isolates, representing 61% of the total isolates studied ( Table 2) . Thirty-two profiles were found in 2 to 9 isolates, representing 28% of the isolates studied, and 44 profiles were found only in 1 isolate, representing 11% of the total isolates studied. Although unique profiles were detected in all countries except Denmark and Norway, most of the unique profiles were found only in 1 or 2 isolates.
The five common profiles BpSR11, BpSR10, BpSR3, BpSR5, and BpSR12 belonged to clusters IV␤, IV␣, IV␣, IV␤, and IV␥, respectively, in the previous EUpertstrain II study (28) . However, with the use of the new version of BioNumerics software in the present EUpertstrain III study, the profiles BpSR3 and BpSR5 were found in a different place but did belong to the cluster IV (Fig. 1) . Table 2 shows the 5 PFGE profiles representing 15% to 90% of the isolates from each country with the exception of Poland. The broad distribution of these profiles suggests that these isolates spread rapidly through Europe.
The most common profile, BpSR11, belonging to cluster IV␤, was observed in the whole study period, representing 23% of the total isolates. This profile was found in proportions of 5% to 45% The second most common PFGE profile, BpSR10, belonging to cluster IV␣, was also observed in the whole study period, representing 13% of the total isolates (Table 2) The fourth most common PFGE profile, BpSR5, also falling into cluster IV, was found in the whole study period, representing 8% of the total isolates studied. This profile was seen in proportions of 4% to 15% in the period from The fifth most common PFGE profile, BpSR12, belonging to cluster IV␥, was also found in the whole study period, representing 5% of the total isolates tested. This profile was seen in proportions of 0% to 10% in the period from The distribution of the 5 common PFGE profiles in the three study periods is shown in Fig. 2 . The major profile, BpSR11, For the minor profiles, BpSR173 was found in France, Germany, The Netherlands, and Sweden (at frequencies of 2%, 9%, 2%, and 2%, respectively), and BpSR19 was found in Finland, Sweden, and The Netherlands (at frequencies of 2%, 3%, and 10%, respectively). The profile BpSR257 was found only in Norway and Finland (at frequencies of 5% and 14%, respectively), BpSR7 was found only in Finland and Sweden (at frequencies of 5% and 5%, respectively), BpSR13 was found only in Denmark and Sweden (at frequencies of 5% and 8%, respectively), and BpSR243 was found only in Germany and Denmark (at frequencies of 3% and 9%, respectively).
Isolates from Finland, France, The Netherlands, and Sweden were available from all three periods. In addition to the change in proportions of the 5 major profiles, a shift in the minor or unique PFGE profiles was also observed with time. Among the 13 Polish isolates, there were 7 distinct PFGE profiles identified from isolates collected in the period from 2004 to 2005. None of the isolates belonged to the five common profiles. Two profiles, together representing four isolates, were unique. The remaining 5 were minor profiles, and some of them had been recovered in Sweden and Germany as well. Table 3 shows proportions of the five predominant PFGE profiles in three different age groups of subjects included in the study period from 2007 to 2009. No difference was noticed in frequencies of the five PFGE profiles between infants Յ2 months of age (unvaccinated) and those in older age groups. Furthermore, we did not observe a relationship between the vaccination programs ( Table 1 ) used and the distribution of PFGE profiles among the participating countries. Furthermore, changes from the wholecell vaccine to the acellular vaccine did not seem to have a direct influence on the distribution of profiles. It should be noted, however, that none of the isolates from Poland, where the whole-cell vaccine is still in use, belonged to the 5 most common profiles found in countries where the acellular vaccine was used, although there were too few isolates for final conclusions to be made.
DISCUSSION
In this study, we analyzed and compared B. pertussis isolates collected from nine European countries with different vaccination programs during a 10-year period. All isolates were tested by the same method at the same institution. This type of analysis allows the identification of highly fit isolates which have increased capacity to spread in an immunized population.
Indeed, we identified common PFGE profiles dominant in Europe. BpSR11, BpSR10, BpSR3, BpSR5, and BpSR12 represent examples of the dynamic change observed in B. pertussis populations. The B. pertussis strain BpSR11 was isolated first in France around 1996 (19) , in Sweden in 1997 (16) , and later in Finland in 1999 (13) . Of the 20 Dutch isolates collected in the period from 1998 to 2001, 6 were found to be BpSR11. Isolates sharing the profile increased in frequency, and it has since become the most common profile in the three countries. During the 10-year study period, frequencies of BpSR11 increased from 26% in 1998 to (33) (34) (35) . With the exception of fim3-4, which carries a silent mutation, all alleles have single-nucleotide polymorphisms (SNPs) that alter the amino acid sequences (35) . The difference between the products of the fim3-1 and fim3-2 alleles is a replacement of alanine by glutamic acid (35) . Moreover, all strains used for production of whole-cell or acellular vaccines analyzed harbor the fim3-1 allele (33, 34) . In The Netherlands, when 704 B. pertussis isolates collected from 1949 to 2010 were studied, only fim3-1 and fim3-2 were detected (36 Recently, the emergence of isolates with a novel allele (ptxP3) for the B. pertussis toxin promoter was described (20) . The ptxP3 isolates were found to produce more pertussis toxin (20) and have spread worldwide (18, 20, 21, 23) . When 138 isolates with the major PFGE profiles (BpSR11-cluster IV␤, BpSR10-cluster IV␣, BpSR12-cluster IV␥, BpSR5-cluster IV, or BpSR3-cluster IV) identified in the present study were analyzed, they all contained the ptxP3 allele (data not shown), suggesting that these isolates have increased fitness and capacity to spread among immunized populations. As yet it is not clear if and to what extent the ptxP3 allele contributed to the increased fitness of ptxP3 strains. For example, the ptxP3 allele may be linked to other loci which affect strain properties. Further research is required to resolve this issue.
In France, where the surveillance of clinical isolates has been performed since 1990 and where acellular vaccines were introduced in 1998, B. pertussis isolates which do not express PT, FHA, or PRN have been isolated (22) . These isolates were detected sporadically even during the prevaccine era. However, in France, 7 years after the introduction of acellular pertussis vaccines, the prevalence of PRN deficient isolates had increased in frequency (22, 24) , and patients infected by PRN-deficient isolates were found to have typical pertussis symptoms. The increased prevalence of PRN-deficient isolates has been also reported in Japan, where the acellular vaccines were introduced in the early 1980s (25) . When isolates belonging to the study period from 2007 to 2009 were analyzed, PRN-deficient isolates were detected among those isolates from France, Norway, and Sweden. All the PRNdeficient isolates were associated with the profile BpSR11, BpSR10, or BpSR3 (reference 22 and data not shown).
In this study, the vaccination status was available for only some of the subjects, and the number of clinical isolates included in each study period was limited. Therefore, it is not possible to directly compare B. pertussis isolated from (partially) vaccinated individuals with that from unvaccinated individuals. However, according to the vaccination programs used in each country, infants younger than 2 months of age can be considered unvaccinated. It seems that there were no significant differences between the isolates from infants too young to be vaccinated and those from older children and adults. Further comparative studies based on a larger number of isolates are needed.
Representative samples are important for the interpretation of results and conclusions. In this study, most of the countries have followed the selection criteria described. It is possible for some countries that due to the limited number of strains collected, the isolates selected might not be representative. However, in countries such as Finland, France, The Netherlands, and Sweden, where the serial collection of isolates was done and tested, the frequencies in the major profiles observed were similar to those found in the present study. Moreover, a recent Polish study reported that there were 59 PFGE profiles identified among 110 isolates from 1995 to 2005 (38) . Most of these profiles were different from those observed in this study, confirming that the trends/ proportions observed in this study were representative.
In conclusion, common PFGE profiles were identified in B. pertussis populations circulating in European countries with different vaccination programs, and these prevalent profiles contain the novel ptxP3 allele. Further, there is evidence for diversification within ptxP3 isolates characterized by distinct PFGE profiles but corresponding to the same PFGE group IV. This work supports the view that the B. pertussis population is adapting even within the relatively short time span covered by this investigation. Further analyses may elucidate how B. pertussis is able to resurge in vaccinated populations according to the vaccine type and the vaccine coverage.
